证券代码：600079 证券简称：人福医药 公告编号：2025-105 人福医药集团股份公司 关于召开2025年第四次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 召开的日期时间：2025 年 9 月 12 日 14 点 00 分 召开地点：武汉市东湖高新区高新大道 666 号人福医药集团会议室 网络投票起止时间：自2025 年 9 月 12 日 至2025 年 9 月 12 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股东会召 开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互联网投票平台的投 票时间为股东会召开当日的 9:15-15:00。 (六) 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 投票股东类型 序号 议案名称 A 股股东 非累积投票议案 关于续聘大信会计师事务所（特殊普通合伙）为公司 2025 年度审计机构的议案 关于与招商局集团财务有限公司签订《金融服务协议》暨 涉及融资融券、转融通业务、 ...

Core Viewpoint - The report highlights the financial performance and operational strategies of Renfu Pharmaceutical Group Co., Ltd. for the first half of 2025, indicating a slight decline in revenue but an increase in net profit, reflecting the company's resilience in a competitive market environment [2][3]. Company Overview and Financial Indicators - Renfu Pharmaceutical is a leading pharmaceutical manufacturer in Hubei Province and ranks among the top 20 in China's pharmaceutical industry [2]. - The company reported a total revenue of approximately 12.06 billion RMB, a decrease of 6.20% compared to the same period last year [2][15]. - The total profit amounted to approximately 1.79 billion RMB, showing a slight increase of 0.77% year-on-year [2][15]. - The net profit attributable to shareholders was approximately 1.15 billion RMB, reflecting a growth of 3.92% compared to the previous year [2][15]. - The company's total assets reached approximately 37.56 billion RMB, an increase of 2.87% from the end of the previous year [2][15]. Industry Context - The pharmaceutical industry is characterized as a crucial part of the national economy, with demand being relatively inelastic and less affected by macroeconomic fluctuations [3]. - The global pharmaceutical market is experiencing stable growth driven by factors such as population growth, aging demographics, and enhanced healthcare awareness [3]. - Recent government policies in China emphasize the importance of healthcare, aiming to improve the healthcare system and promote the pharmaceutical sector [3]. Business Operations and Product Lines - Renfu Pharmaceutical focuses on a comprehensive product line that includes anesthetics, steroid hormones, and Uyghur medicine, establishing a leading position in these segments [3][6]. - The company operates under a group management model, where the headquarters sets strategic goals while subsidiaries manage specialized operations [6]. - The company has a total of 587 drug production approvals, including 43 exclusive products, indicating a strong product portfolio [6][12]. Financial Performance Analysis - The company’s operating costs decreased by 8.67% to approximately 6.25 billion RMB, while sales expenses also saw a reduction of 7.04% [15]. - Research and development expenses increased by 5.32% to approximately 743 million RMB, reflecting the company's commitment to innovation [15]. - The net cash flow from operating activities was approximately 858 million RMB, a slight increase of 1.48% year-on-year [15]. Strategic Initiatives - The company is actively pursuing international expansion, with over 80 products exported to more than 70 countries [3]. - Renfu Pharmaceutical is enhancing its marketing and distribution networks to improve service delivery and market penetration [6][13]. - The company is focusing on innovation and R&D, with significant investments in developing new drugs and improving existing product lines [14].

Core Viewpoint - Renfu Pharmaceutical Group Co., Ltd. reported a decrease in revenue for the first half of 2025, with total revenue of approximately 12.06 billion yuan, a decline of 6.20% compared to the same period last year [1]. Company Overview - The total assets of the company at the end of the reporting period were approximately 37.56 billion yuan, an increase of 2.87% from the previous year [1]. - The net assets attributable to shareholders of the listed company were approximately 18.34 billion yuan, reflecting a growth of 4.04% year-on-year [1]. - The net profit attributable to shareholders for the reporting period was approximately 1.15 billion yuan, an increase of 3.92% compared to the same period last year [1]. - The basic earnings per share for the reporting period were 0.71 yuan, up by 4.41% from 0.68 yuan in the previous year [1]. Shareholder Structure - As of the end of the reporting period, the total number of shareholders was 50,062 [1]. - The top ten shareholders collectively controlled 24.70% of the voting rights of the company [2]. - The new controlling shareholder is招商生科 (China Merchants Life Science), with the actual controller being招商局集团有限公司 (China Merchants Group) [3].

Core Viewpoint - The independent directors of Renfu Pharmaceutical Group Co., Ltd. held their first special meeting in 2025, where they unanimously approved several proposals related to a financial service agreement with China Merchants Group Finance Co., Ltd. [1][2] Group 1: Financial Service Agreement - The proposed financial service agreement with China Merchants Group Finance Co., Ltd. adheres to principles of equality and voluntariness, with fair pricing that is beneficial for expanding the company's financing channels [1] - The decision-making process for the related party transaction complies with relevant laws and regulations, as well as the company's articles of association, ensuring no harm to the interests of the company and its shareholders, particularly minority shareholders [1] Group 2: Risk Assessment Report - The risk assessment report regarding China Merchants Group Finance Co., Ltd. is deemed objective and fair, accurately reflecting the financial company's operational qualifications, business, and risk status [2] - The report is approved for submission to the company's board of directors for further review [2] Group 3: Risk Disposal Plan - The risk disposal plan formulated for conducting financial business with China Merchants Group Finance Co., Ltd. is designed to effectively prevent, control, and mitigate risks associated with the financial operations, ensuring the safety of the company's funds [2] - This plan is also approved for submission to the company's board of directors for further consideration [2]

Core Points - The board of directors of Renfu Pharmaceutical Group Co., Ltd. held its second meeting on August 26, 2025, to discuss various proposals and resolutions [1][2][3] Meeting Details - The meeting was attended by all nine directors, with four participating in person and the rest voting via communication [1] - The meeting was deemed legally valid and compliant with relevant regulations and the company's articles of association [1] Resolutions Passed - The board approved the full and summary reports for the company's 2025 semi-annual report, which had previously been reviewed by the audit committee [2] - The board agreed to reappoint Da Xin Certified Public Accountants as the auditing firm for the 2025 financial year, with the 2024 audit fees totaling 5.2 million yuan, including 1.5 million yuan for internal control audits [2][3] - A financial services agreement with China Merchants Group Finance Co., Ltd. was approved, pending shareholder approval [3][4] - The board also approved a risk assessment report regarding China Merchants Group Finance Co., Ltd. [4] - A risk disposal plan for financial business with China Merchants Group Finance Co., Ltd. was also approved [5] Upcoming Events - The board scheduled the fourth extraordinary general meeting for September 12, 2025, to review the reappointment of the auditing firm and the financial services agreement [5][6]

格隆汇8月27日｜人福医药(600079.SH)公告称，人福医药集团股份公司发布了2025年半年度报告，报告 显示，公司营业收入为120.64亿元，同比下降6.20%；归属于上市公司股东的净利润为11.55亿元，同比 增长3.92%。 ...

人福医药集团股份公司2025 年半年度报告 公司代码：600079 公司简称：人福医药 人福医药集团股份公司 2025 年半年度报告 二〇二五年八月 1 / 191 人福医药集团股份公司2025 年半年度报告 重要提示 一、 本公司董事会及董事、高级管理人员保证半年度报告内容的真实性、准确性、完整性，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人杜文涛、主管会计工作负责人杜文涛及会计机构负责人（会计主管人员）何华 琴声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的前瞻性陈述不构成公司对投资者的实质承诺，敬请广大投资者注意投资风 险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 公司已在本报告中详细描述 ...

证券代码:600079 证券简称:人福医药 编号:临2025-104 人福医药集团股份公司 关于拟签订《金融服务协议》暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示 ● 人福医药集团股份公司（以下简称"人福医药"或"公司"）拟与招商局集团 财务有限公司（以下简称"招商局财务公司"）签订《金融服务协议》，招商局财务公 司为公司提供存款、结算、信贷、外汇及其他金融服务，并约定本公司在招商局财务 公司日终存款余额不超过人民币 2 亿元，招商局财务公司向本公司授出的每日最高未 偿还贷款结余不得超过人民币 5 亿元；协议期限三年。 ● 招商局财务公司为本公司大股东招商生命科技（武汉）有限公司（以下简称"招 商生科"）的实际控制人招商局集团有限公司（以下简称"招商局集团"）的全资子公 司，根据《上海证券交易所股票上市规则》的相关规定，本次交易构成关联交易。 ● 本次交易不构成重大资产重组。 ● 本次交易尚需提交公司股东会审议，关联股东将在股东会审议本议案时回避表 决。 ● 过去 12 个月内，公司及下属子 ...

根据《上海证券交易所上市公司自律监管指引第 5 号——交易与关联交易》 的要求，人福医药集团股份公司（以下简称"公司"、"本公司"）与招商局集 团财务有限公司（以下简称"招商局财务公司"）作为关联方，须以公正、合理 的原则对本公司与财务公司之间的存、贷款等关联交易进行定期风险评估。本公 司查验了招商局财务公司《金融许可证》《营业执照》等证件资料，审阅了招商 局财务公司资产负债表、利润表、现金流量表等定期财务报告，对招商局财务公 司的经营资质、业务和风险状况进行了评估，现将有关风险评估情况报告如下： 一、 招商局财务公司基本情况 招商局财务公司是具有企业法人地位的非银行金融机构。招商局财务公司企 业信息如下： 金融许可证机构编码：L0125H211000001； 统一社会信用代码：9111000071782949XA； 人福医药集团股份公司 关于对招商局集团财务有限公司的风险评估报告 注册资本：人民币 50 亿元； 法定代表人：吴泊； 公司注册地址：北京市朝阳区安定路 5 号院 10 号楼 B 栋 15 层 1501； 企业类型：其他有限责任公司； 业务范围包括：吸收成员单位存款；办理成员单位贷款；办理成员单位 ...

证券代码：600079 证券简称：人福医药 编号：临 2025-103 人福医药集团股份公司 关于续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示 ● 拟续聘的会计师事务所名称：大信会计师事务所（特殊普通合伙） ● 本事项尚需提交公司股东会审议 人福医药集团股份公司（以下简称"公司"）第十一届董事会第二次会议审议并 通过了《关于续聘大信会计师事务所（特殊普通合伙）为公司 2025 年度审计机构的 议案》，同意公司续聘大信会计师事务所（特殊普通合伙）（以下简称"大信事务所"） 为公司 2025 年度财务报告审计机构及内部控制审计机构，并同意将该预案提交股东 会审议。现将相关情况公告如下： 一、拟续聘会计师事务所的基本情况 （一）机构信息 1、基本信息 大信事务所成立于 1985 年，2012 年 3 月转制为特殊普通合伙制事务所，总部位 于北京，注册地址为北京市海淀区知春路 1 号 22 层 2206。大信事务所在全国设有 33 家分支机构，在香港设立了分所，并于 2017 年发起设立了大信 ...